CytomX (CTMX) CLO Alejandra Carvajal Receives RSUs & Options

What Happened

• Alejandra Carvajal, Chief Legal Officer of CytomX Therapeutics (CTMX), received equity awards reported on Aug 3, 2026: a grant of 100,000 restricted stock units (RSUs) and a derivative award covering 450,000 shares. Both entries show an acquisition price of $0.00 (standard for equity grants), so no cash was exchanged on grant.

Key Details

• Transaction date: August 3, 2026; Form 4 filed Aug 5, 2026 (timely filing).
• Reported amounts: 100,000 RSUs (separately listed) and a 450,000-share derivative award (filing notes that 100,000 of the total relate to RSUs).
• Price: $0.00 per share (grant/award).
• Shares owned after transaction: not specified in the filing.
• Footnotes:
  • F1: The 100,000 RSUs convert to one share each upon vesting; 25% vests annually on September 15, starting Sept 15, 2027, subject to continued service.
  • F3: The derivative portion vests 25% one year after the Aug 3, 2026 vesting-commencement date, then 1/48th monthly so the award is fully vested after four years, subject to continued service.
• No mention of a 10b5-1 plan, tax-withholding sale, or immediate sale of shares in the filing.

Context

• These are compensation awards (not purchases or sales) commonly used to retain executives. RSUs deliver shares only when they vest; the derivative award appears to be time‑based equity that vests over four years.
• Because no shares were sold or bought on the market, this filing does not represent a bullish or bearish trading signal—it's a standard grant tied to ongoing service.